

SUPPLEMENTARY MATERIALS

Supplementary Table 1. Estimated numbers of individuals living with metastatic cancer on January 1, 2018, by cancer type and years since metastatic diagnosis

Cancer type	Total N	Years since diagnosis							
		0 - <2		2-<5		5-<10		10+	
		n	%	n	%	n	%	n	%
Lung and Bronchus	174,090	97,205	55.8	39,987	23.0	21,180	12.2	15,718	9.0
Breast (female)	140,230	54,233	38.7	37,225	26.5	21,889	15.6	26,883	19.2
Colon and Rectum	133,234	56,026	42.1	29,767	22.3	20,130	15.1	27,311	20.5
Prostate (male)	120,368	53,418	44.4	34,208	28.4	19,905	16.5	12,837	10.7
Melanoma	39,716	10,901	27.4	9,812	24.7	7,683	19.3	11,320	28.5
Bladder	15,767	9,089	57.6	3,058	19.4	1,637	10.4	1,983	12.6

Supplementary Table 2. Number of people and one-year relative survival in percentage (95% confidence interval) for people diagnosed with de novo metastatic cancer in the SEER-18 areas by grouped age (0-85+) and year at diagnosis.^a

Cancer type	Age, y	De novo Relative Survival (2000-2005)		De novo Relative Survival (2006-2011)		De novo Relative Survival (2012-2017)	
		N	1-yr Relative Survival (95% CI)	N	1-yr Relative Survival (95% CI)	N	1-yr Relative Survival (95% CI)
Bladder	0-49	209	40% [33%, 46%]	200	40% [33%, 47%]	210	44% [37%, 51%]
	50-64	693	33% [29%, 36%]	865	37% [34%, 41%]	1,181	33% [30%, 35%]
	65-74	712	30% [26%, 33%]	841	29% [26%, 32%]	1,175	32% [29%, 35%]
	75-84	773	20% [18%, 24%]	864	23% [20%, 26%]	984	24% [21%, 26%]
	85+	282	12% [8%, 17%]	351	16% [12%, 20%]	454	12% [9%, 16%]
	0+	2,669	27% [25%, 29%]	3,121	29% [27%, 31%]	4,004	29% [27%, 30%]
Breast (female)	0-49	2,655	69% [67%, 71%]	3,450	77% [76%, 79%]	3,731	79% [77%, 80%]
	50-64	4,532	61% [60%, 63%]	6,063	66% [65%, 67%]	7,010	69% [68%, 71%]
	65-74	2,578	52% [50%, 54%]	3,112	59% [57%, 61%]	4,071	60% [59%, 62%]
	75-84	2,278	42% [40%, 44%]	2,301	46% [43%, 48%]	2,605	49% [47%, 51%]
	85+	872	34% [30%, 37%]	1,057	36% [33%, 39%]	1,213	35% [32%, 39%]
	0+	12,915	56% [55%, 57%]	15,983	62% [61%, 63%]	18,630	64% [63%, 65%]
Colon and Rectum	0-49	4,725	65% [64%, 66%]	5,606	73% [71%, 74%]	6,366	75% [74%, 76%]
	50-64	11,074	60% [59%, 61%]	12,984	64% [63%, 65%]	14,729	64% [64%, 65%]
	65-74	8,863	46% [45%, 47%]	8,253	54% [52%, 55%]	9,268	55% [54%, 56%]
	75-84	8,347	33% [32%, 34%]	6,959	38% [37%, 39%]	6,207	37% [35%, 38%]
	85+	3,247	20% [19%, 22%]	3,397	21% [20%, 23%]	3,225	22% [20%, 24%]
	0+	36,256	48% [47%, 48%]	37,199	55% [54%, 55%]	39,795	56% [56%, 57%]
Lung and Bronchus	0-49	9,207	32% [31%, 33%]	7,794	38% [37%, 40%]	5,283	46% [45%, 48%]
	50-64	39,804	28% [27%, 28%]	42,645	32% [31%, 32%]	41,090	35% [34%, 35%]
	65-74	40,058	23% [22%, 23%]	39,912	27% [26%, 27%]	41,514	30% [30%, 31%]
	75-84	31,539	17% [17%, 18%]	31,444	21% [20%, 21%]	28,424	24% [23%, 24%]
	85+	7,570	12% [11%, 13%]	9,543	14% [14%, 15%]	9,640	16% [15%, 17%]
	0+	128,178	23% [23%, 23%]	131,338	27% [27%, 27%]	125,951	30% [30%, 30%]
Melanoma	0-49	611	42% [38%, 46%]	636	47% [43%, 51%]	716	63% [59%, 67%]
	50-64	829	40% [36%, 43%]	1,167	43% [40%, 46%]	1,481	55% [52%, 58%]
	65-74	532	41% [37%, 46%]	647	41% [37%, 45%]	961	51% [48%, 54%]
	75-84	448	36% [31%, 40%]	505	34% [30%, 38%]	658	45% [41%, 49%]
	85+	161	30% [22%, 38%]	214	36% [29%, 43%]	296	43% [37%, 49%]
	0+	2,581	39% [37%, 41%]	3,169	42% [40%, 43%]	4,112	53% [52%, 55%]
Prostate (male)	0-49	320	83% [78%, 87%]	352	83% [79%, 87%]	354	90% [86%, 93%]
	50-64	2,986	82% [80%, 83%]	3,896	84% [83%, 85%]	5,404	86% [85%, 87%]
	65-74	3,689	79% [77%, 80%]	3,826	79% [78%, 80%]	6,136	83% [82%, 84%]
	75-84	4,073	70% [68%, 71%]	3,741	71% [70%, 73%]	5,002	75% [74%, 76%]
	85+	1,736	58% [55%, 60%]	2,000	57% [54%, 60%]	2,962	65% [62%, 67%]
	0+	12,804	74% [73%, 75%]	13,815	76% [75%, 76%]	19,858	79% [79%, 80%]

^aRelative survival is presented for both sexes combined unless otherwise stated.

Supplementary Table 3. Number of people and five-year relative survival in percentage (95% confidence interval) for people diagnosed with de novo metastatic cancer in the SEER-18 areas by grouped age (0-85+) and year at diagnosis.^a

Cancer type	Age, y	De novo Relative Survival (2000-2005)		De novo Relative Survival (2006-2011)		De novo Relative Survival (2012-2017)	
		N	5-yr Relative Survival (95% CI)	N	5-yr Relative Survival (95% CI)	N	5-yr Relative Survival (95% CI)
Bladder	0-49	209	12% [8%, 17%]	200	8% [5%, 13%]	210	12% [7%, 18%]
	50-64	693	7% [5%, 9%]	865	6% [5%, 8%]	1,181	8% [6%, 10%]
	65-74	712	5% [4%, 7%]	841	5% [3%, 6%]	1,175	8% [6%, 10%]
	75-84	773	4% [3%, 6%]	864	4% [3%, 6%]	984	6% [4%, 9%]
	85+	282	3% [1%, 7%]	351	4% [2%, 8%]	454	4% [2%, 8%]
	0+	2,669	6% [5%, 7%]	3,121	5% [4%, 6%]	4,004	7% [6%, 8%]
Breast (female)	0-49	2,655	22% [20%, 23%]	3,450	28% [27%, 30%]	3,731	32% [29%, 34%]
	50-64	4,532	18% [16%, 19%]	6,063	20% [18%, 20%]	7,010	22% [21%, 23%]
	65-74	2,578	13% [12%, 15%]	3,112	17% [16%, 19%]	4,071	20% [18%, 22%]
	75-84	2,278	10% [8%, 11%]	2,301	13% [11%, 14%]	2,605	14% [12%, 16%]
	85+	872	9% [7%, 12%]	1,057	9% [7%, 12%]	1,213	7% [5%, 10%]
	0+	12,915	16% [15%, 16%]	15,983	19% [19%, 20%]	18,630	21% [21%, 22%]
Colon and Rectum	0-49	4,725	16% [15%, 17%]	5,606	20% [19%, 21%]	6,366	22% [20%, 23%]
	50-64	11,074	13% [13%, 14%]	12,984	17% [16%, 17%]	14,729	18% [17%, 18%]
	65-74	8,863	11% [10%, 11%]	8,253	13% [13%, 14%]	9,268	15% [14%, 16%]
	75-84	8,347	7% [6%, 8%]	6,959	8% [7%, 9%]	6,207	8% [7%, 9%]
	85+	3,247	6% [4%, 7%]	3,397	4% [4%, 6%]	3,225	6% [4%, 7%]
	0+	36,256	11% [11%, 11%]	37,199	14% [14%, 14%]	39,795	15% [15%, 16%]
Lung and Bronchus	0-49	9,207	6% [5%, 6%]	7,794	8% [7%, 9%]	5,283	13% [12%, 14%]
	50-64	39,804	4% [4%, 5%]	42,645	6% [5%, 6%]	41,090	8% [8%, 9%]
	65-74	40,058	3% [3%, 3%]	39,912	4% [4%, 5%]	41,514	6% [6%, 7%]
	75-84	31,539	2% [2%, 2%]	31,444	3% [3%, 3%]	28,424	5% [4%, 5%]
	85+	7,570	2% [1%, 2%]	9,543	2% [2%, 3%]	9,640	3% [2%, 4%]
	0+	128,178	3% [3%, 4%]	131,338	5% [4%, 5%]	125,951	7% [7%, 7%]
Melanoma	0-49	611	18% [15%, 21%]	636	24% [20%, 27%]	716	38% [34%, 42%]
	50-64	829	17% [14%, 19%]	1,167	19% [17%, 22%]	1,481	33% [30%, 36%]
	65-74	532	14% [11%, 17%]	647	17% [14%, 20%]	961	30% [27%, 34%]
	75-84	448	13% [9%, 17%]	505	14% [11%, 18%]	658	22% [17%, 27%]
	85+	161	8% [3%, 17%]	214	10% [5%, 17%]	296	19% [9%, 31%]
	0+	2,581	15% [14%, 17%]	3,169	18% [17%, 20%]	4,112	31% [29%, 33%]
Prostate (male)	0-49	320	30% [25%, 35%]	352	28% [23%, 33%]	354	25% [19%, 32%]
	50-64	2,986	32% [30%, 33%]	3,896	34% [33%, 36%]	5,404	35% [33%, 37%]
	65-74	3,689	34% [32%, 36%]	3,826	34% [33%, 36%]	6,136	35% [33%, 37%]
	75-84	4,073	26% [25%, 28%]	3,741	28% [26%, 30%]	5,002	29% [27%, 32%]
	85+	1,736	20% [17%, 24%]	2,000	18% [15%, 21%]	2,962	16% [13%, 19%]
	0+	12,804	29% [28%, 30%]	13,815	30% [30%, 31%]	19,858	31% [30%, 32%]

^a Relative survival is presented for both sexes combined unless otherwise stated.